在患有复发/逆转多发性髓瘤的患者中对马格罗利马布组合进行第二阶段多臂研究的最终结果
Barry Paul1, Jiri Minarik2, Francesca Cottini3
1Atrium Health Levine Cancer Institute Wake Forest University School of Medicine Charlotte North Carolina USA.
EJHaem
|June 9, 2025
概括
这项研究研究了对复发性/耐药性多发性髓瘤 (RRMM) 的magrolimab组合. 虽然Magrolimab加Carfilzomib/dexamethasone显示出有希望的结果,但由于研究早期结束,整体见解有限.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床试验 临床试验
背景情况:
- 预先治疗复发性/耐药性多发性骨髓瘤 (RRMM) 是一个重大的临床挑战,治疗选择有限.
- 对于新,安全和有效的治疗方法,在RRMM患者中提供持久反应,有着极大的需求.
研究的目的:
- 在RRMM患者中评估magrolimab与达拉图马布,波马利多米德/德克萨米或卡菲尔佐米布/德克萨米联合使用的疗效和安全性.
- 确定客观反应率 (ORR) 作为这些基于magrolimab的疗法的主要疗效终点.
主要方法:
- 进行了一项第二阶段研究,涉及RRMM患者接受了马格罗利马布与达拉图穆马布,波马利多米德/德克萨米沙或卡菲尔佐米布/德克萨米沙联合治疗.
- 评估的主要疗效终点是客观反应率 (ORR). 通过不良事件 (AE) 监测来评估安全性.
主要成果:
- 观察到的客观反应率 (ORR) 为magrolimab加daratumumab的14.3%,magrolimab加pomalidomide/dexamethasone的20.0%,magrolimab加carfilzomib/dexamethasone的36.4%.
- 剂量限制性毒性包括发烧性中性和输液相关反应. 与马格罗利马布相关的3级以上的不良事件发生在60-64%的患者中. 两例死亡与AE有关,但没有归因于magrolimab.
结论:
- 马格罗利马布与carfilzomib/dexamethasone的组合在这个第二阶段研究中显示了较高的ORR与其他疗法相比.
- 由于研究提前结束,对RRMM的magrolimab组合的全面临床见解仍然有限. 进一步的调查是有必要的.
更多相关视频
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.1K
10:44Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
13.1K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...